Goldman Sachs Group Inc Incyte Corp Put Options Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $1.38 Million - $1.71 Million	26,900 New	26,900 $1.63 Million
Q3 2023 May 14, 2024	BUY	$57.77 - $65.93 $4.04 Million - $4.62 Million	70,000 New	70,000 $4.04 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $3.36 Million - $3.83 Million	-58,100 Reduced 45.36%	70,000 $4.04 Million
Q2 2023 May 14, 2024	BUY	$60.95 - $75.51 $3.54 Million - $4.39 Million	58,100 Added 83.0%	128,100 $7.97 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $3.54 Million - $4.39 Million	58,100 Added 83.0%	128,100 $7.97 Million
Q1 2023 May 14, 2024	BUY	$70.23 - $86.01 $2.82 Million - $3.45 Million	40,100 Added 134.11%	70,000 $5.06 Million
Q1 2023 May 11, 2023	BUY	$70.23 - $86.01 $2.82 Million - $3.45 Million	40,100 Added 134.11%	70,000 $5.06 Million
Q4 2022 May 14, 2024	BUY	$67.18 - $84.11 $2.01 Million - $2.51 Million	29,900 New	29,900 $2.4 Million
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $2.01 Million - $2.51 Million	29,900 New	29,900 $2.4 Million
Q3 2021 Nov 10, 2021	BUY	$68.67 - $84.02 $5.15 Million - $6.3 Million	75,000 New	75,000 $5.16 Million

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.